ResearcherCentre National de la Recherche ScientifiqueActive in the last 2 years
Sabrina Belbekhouche
Matched on ORCID iD 0000-0002-0636-4425; OpenAlex author ID A5064682899. Sources: OpenAlex.
Their work
- Papers
- 4 (first author 0, last author 1)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 6
2020: 1 paper · 2021: none · 2022: none · 2023: none · 2024: none · 2025: 2 papers · 2026: 1 paper
Papers 4
- Paclitaxel-loaded nanostructured lipid carriers surface-functionalized with N6L for pancreatic cancer. Last author DOI 10.1016/j.biopha.2026.119797↗
- The nucleolin antagonist N6L and paclitaxel combination treatment could be a new promising therapeutic strategy for pancreatic ductal adenocarcinoma therapy. Co-author DOI 10.1016/j.ejphar.2025.177310↗
- Corrigendum to "The nucleolin antagonist N6L and paclitaxel combination treatment could be a new promising therapeutic strategy for pancreatic ductal adenocarc… Co-author DOI 10.1016/j.ejphar.2025.177383↗
- Fabrication of large pore mesoporous silica microspheres by salt-assisted spray-drying method for enhanced antibacterial activity and pancreatic cancer treatme… Co-author DOI 10.1016/j.ijpharm.2020.119930↗
Closest collaborators
The 6 strongest of 6 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Ilaria Cascone · 4 shared papers, 2020–2026 · strength 0.90
- Paper Paclitaxel-loaded nanostructured lipid carriers surface-functionalized with N6L for pancreatic cancer. DOI 10.1016/j.biopha.2026.119797↗
- Paper The nucleolin antagonist N6L and paclitaxel combination treatment could be a new promising therapeutic strategy for pan… DOI 10.1016/j.ejphar.2025.177310↗
- Paper Corrigendum to "The nucleolin antagonist N6L and paclitaxel combination treatment could be a new promising therapeutic … DOI 10.1016/j.ejphar.2025.177383↗
- Benedetta Ferrara · 3 shared papers, 2020–2025 · strength 0.59
- Paper The nucleolin antagonist N6L and paclitaxel combination treatment could be a new promising therapeutic strategy for pan… DOI 10.1016/j.ejphar.2025.177310↗
- Paper Corrigendum to "The nucleolin antagonist N6L and paclitaxel combination treatment could be a new promising therapeutic … DOI 10.1016/j.ejphar.2025.177383↗
- Paper Fabrication of large pore mesoporous silica microspheres by salt-assisted spray-drying method for enhanced antibacteria… DOI 10.1016/j.ijpharm.2020.119930↗
- Fabrice Raineri · 2 shared papers, 2025 · strength 0.47
- Paper The nucleolin antagonist N6L and paclitaxel combination treatment could be a new promising therapeutic strategy for pan… DOI 10.1016/j.ejphar.2025.177310↗
- Paper Corrigendum to "The nucleolin antagonist N6L and paclitaxel combination treatment could be a new promising therapeutic … DOI 10.1016/j.ejphar.2025.177383↗
- José Laurent Cohen · 2 shared papers, 2025 · strength 0.47
- Paper The nucleolin antagonist N6L and paclitaxel combination treatment could be a new promising therapeutic strategy for pan… DOI 10.1016/j.ejphar.2025.177310↗
- Paper Corrigendum to "The nucleolin antagonist N6L and paclitaxel combination treatment could be a new promising therapeutic … DOI 10.1016/j.ejphar.2025.177383↗
- Laura Larue · 1 shared paper, 2026 · strength 0.32
- Alfred P. Weber · 1 shared paper, 2020 · strength 0.11
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.